Compare AbbVie Inc (ABBV) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Marsh & McLennan Companies, Inc. — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while Marsh & McLennan Companies, Inc. trades at $178.68 (market cap $85.76B). The key difference: AbbVie Inc is far larger — about 5.2× Marsh & McLennan Companies, Inc.'s market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MRSH | |
|---|---|---|
Market Cap | $449.91B | $85.76B |
Sector | Health | Financials |
52-Week High | $261.07 | $214.71 |
52-Week Low | $184.85 | $157.32 |
Enterprise Value | $513.38B | $106.60B |
Dividend Yield | 2.72% | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
Marsh (MRSH) trades at $178.00, showing modest daily weakness (-0.3%) but maintaining a bullish technical trend above key support levels. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $3.29 exceeding expectations, and robust profitability metrics with 14.26% net income margin and 27.42% ROE. Recent acquisition of TriBridge Partners strengthens advisory capabilities while dividend payments provide shareholder returns.
Marsh presents a compelling investment case with analyst consensus target of $192.00 offering 7.9% upside potential. The stock trades at reasonable valuation multiples (P/E 21.84, P/S 3.12) for its quality profile, though rising costs and premium valuation warrant monitoring. Institutional sentiment remains positive with 11 buy ratings outweighing 1 sell recommendation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
